Trials / Completed
CompletedNCT02138045
Treatment of Diabetic Neuropathy With Liraglutide
A Randomized, Double-blinded, Single-centre, Parallel-group, Placebo-controlled, Prospective Trial of Neuroprotective Effect of Liraglutide for Treatment of Diabetic Neuropathy.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Aalborg University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to explore whether liraglutide has a long term effect on clinical symptoms and biomarkers in patients with diabetic neuropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo treatment | Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose. |
| DRUG | Liraglutide treatment | Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose. |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2017-02-01
- Completion
- 2017-02-01
- First posted
- 2014-05-14
- Last updated
- 2021-08-10
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT02138045. Inclusion in this directory is not an endorsement.